Articles related to CLINICAL STUDY

In a prospective study following the diet and activity records of more than 100,000 individuals in France, artificial sweeteners were positively correlated with cardiovascular diseases. Analyzing 900,000 person-years of data showed: Total artificial sweetener intake was associated with CVD risk Artificial sweeteners were more strongly associated with cerebrovascular disease Aspartame was associated with increase cerebrovascular events Acesulfame K and sucralose were associated with increased coronary heart disease risk

Over a 24-year-period, more than 200,000 men (n=46,341) and women (n=159,907) had dietary intake assessments performed every four years via survey. During the period, 3,216 CRC cancer cases were reported. Men with the highest 20% of ultra-processed food consumption had a 29% higher risk of developing colorectal cancer. For women, no association was seen between ultra-processed food consumption and risk of CRC. Ready-to-eat meat products and sugar-sweetened drinks among men and ready-to-eat/heat mixed dishes among women had the highest risk of CRC. Yogurt and dairy-based desserts had a negative associated risk for women.

168 adults with unresectable stage IIIC-IV melanoma with progression after 1 line of systemic treatment (not including ipilimumab) were randomly assigned to receive tumor-infiltrating lymphocyte therapy or ipilimumab. With a median follow-up of nearly 3 years, the median PFS was 7.2 months in the TIL arm and 3.1 months in the ipilimumab arm.

As yet, there are no consensus treatment strategies for class 2 and 3 BRAF mutations. This systematic review and meta-analysis of published reports of patients with class 2 or 3 BRAF mutations from 2010 to 2021 assesses MAPK targeted therapy in the setting. The meta-analysis suggests that MAPK TTs have clinical activity in some class 2 and 3 BRAF-mutant cancers.

Resistance to immune checkpoint inhibitors is common. In a prior phase Ib study, the combination of talimogene laherparepvec (T-VEC) pembrolizumab demonstrated an encouraging complete response rate and acceptable safety profile in patients with advanced melanoma. In this phase III, randomized, double-blind, multicenter, international study, the combination of T-VEC-pembrolizumab did not statistically improve PFS or OS vs placebo-pembrolizumab. However, T-VEC-pembrolizumab demonstrated a numerical PFS improvement without new safety signals.

This cohort study discovered that depression, anxiety, perceived stress, loneliness, and worry about COVID-19 were prospectively associated with a 1.3- to 1.5-fold increased risk of self-reported post-COVID-19 conditions, as well as an increased risk of daily life impairment related to post-COVID-19 conditions.